COVID-19 preclinical drug development database
"The Academy's database maps the landscape of preclinical COVID-19 research in the UK. By submitting their projects to the database, preclinical researchers from academia and industry alike are doing their part to help identify and prioritise important preclinical COVID-19 research, to help build treatments and research tools for a COVID-19-resilient future."
Professor Michael Malim FRS FMedSci, Expert Group Chair and Professor of Infectious Diseases and Head of School of Immunology & Microbial Sciences, King's College London
Around the world researchers are driving forward research at an unprecedented pace to tackle the COVID-19 pandemic. We aim to provide a comprehensive overview of research into developing novel therapeutic targets, new molecular entities and repurposing existing medicines.
We welcome and encourage contributions of a range of types from both academia and industry. We are interested in collating information on two main types of research:
"As the pandemic matures and we prepare for the future, we look increasingly to preclinical researchers to develop therapies to fight COVID-19 and the SARS-CoV-2 virus in years to come. The database helps researchers and funders avoid duplication of effort and find useful collaborators and initiatives, like the LifeArc Advise & Connect service, to move us towards treatments for COVID-19 together faster."
Dr Melanie Lee CBE FMedSci, Expert Group Member and Chief Executive Officer, LifeArc
Read the letter from the Academy's President and Vice President, inviting researchers to contribute to this survey: https://acmedsci.ac.uk/file-download/63879858